We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
21 Jun 2021 - 24 Jun 2021

Low-Density Lipoprotein Cholesterol Is Associated with Insulin Secretion

By LabMedica International staff writers
Posted on 02 Jun 2021
Print article
Image: The YSI 2300 STAT Plus Glucose & Lactate Analyzer (Photo courtesy of YSI Life Science)
Image: The YSI 2300 STAT Plus Glucose & Lactate Analyzer (Photo courtesy of YSI Life Science)
Dyslipidemia is characterized by low levels of high-density lipoproteins (HDLs), hypertriglyceridemia, high total and low-density lipoprotein (LDL) cholesterol concentrations, as well as an increased proportion of small dense lipoproteins.

Type 2 diabetes is characterized by insulin resistance and impaired insulin secretion from pancreatic β cells. Insulin resistance alone is insufficient to cause type 2 diabetes, as long as the β cell remains able to compensate for the increased demand for insulin. Once this compensatory mechanism reaches its physiological limits, glucose levels increase and patients progress toward overt type 2 diabetes.

Doctors specializing in Diabetes from the University of Tübingen (Tübingen, Germany) and their colleagues investigated the relationship between LDL cholesterol concentrations and insulin secretion and glucagon levels. A total of 3,039 individuals without cholesterol-lowering therapy, but with increased risk for diabetes, underwent routine blood tests and a 5-point oral glucose tolerance test (OGTT). Glucagon concentrations, insulin secretion, and insulin clearance indices were derived from the OGTT.

Plasma glucose was measured using an YSI 2300 glucose analyzer (YSI Life Science, Yellow Springs, OH, USA). Serum insulin and C-peptide were determined by immunoassay with the ADVIA Centaur XP Immunoassay System (Siemens Healthcare Diagnostics, Erlangen, Germany). Total, HDL, LDL cholesterol, and triglycerides were measured on the Siemens Healthcare Diagnostics ADVIA XPT Clinical Chemistry System. Glycated hemoglobin measurements were performed using the Tosoh A1c analyzer HLC-723G8 (Tosoh Bioscience GmbH, Griesheim, Germany).

The scientists reported that there was association between LDL cholesterol and fasting glucagon or post–glucose load glucagon levels, but they detected significant positive associations of LDL cholesterol and C-peptide–based indices of insulin secretion. In contrast, they found a negative association of insulin-based insulin secretion indices with LDL concentrations. LDL cholesterol levels, however, were positively associated with insulin clearance assessed from C-peptide and insulin concentrations, both in the fasting state and post–glucose load.

The authors concluded that as C-peptide based indices reflect insulin secretion independent of hepatic clearance, their results indicate lower insulin secretion in case of lesser LDL cholesterol. This could explain deteriorating glycemic control in response to cholesterol-lowering drugs. The study was published in the June, 2021 issue of The Journal of Clinical Endocrinology & Metabolism.

Related Links:
University of Tübingen
YSI Life Science
Siemens Healthcare Diagnostics
Tosoh Bioscience


New
Gold Supplier
TRANSPORT MEDIUM
TRANSPORT MEDIUM-2
New
COVID-19 Portable Test Kit
VersaLab Portable
New
Flu & SARS-CoV-2 Test
FlexStar FLU Type & SARS-CoV-2 Detection Mix 1.5
New
Influenza A/B Assay
Influenza A+B One Step Assay

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Illustration

Global Clinical Chemistry Analyzers Market to Reach USD 15.97 Billion by 2028

The global clinical chemistry analyzers market is projected to grow at a CAGR of 4.25% from USD 11.45 billion in 2020 to USD 15.97 billion by 2028, driven by growth in technology, rising global population,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.